Regeneron Pharmaceuticals, Inc. (REGN) Earnings History
Annual and quarterly earnings data from 1991 to 2025
Loading earnings history...
REGN EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
REGN Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 85.4% | 24.9% | 31.4% |
| 2024 | 86.1% | 28.1% | 31.1% |
| 2023 | 82.9% | 33.2% | 30.1% |
| 2022 | 86.0% | 44.2% | 35.6% |
| 2021 | 83.1% | 55.7% | 50.2% |
Download Data
Export REGN earnings history in CSV or JSON format
Free sign-in required to download data
Regeneron Pharmaceuticals, Inc. (REGN) Earnings Overview
As of May 6, 2026, Regeneron Pharmaceuticals, Inc. (REGN) reported trailing twelve-month net income of $4.42B, reflecting +8.2% year-over-year growth. The company earned $41.07 per diluted share over the past four quarters, with a net profit margin of 31.4%.
Looking at the long-term picture, REGN's 5-year EPS compound annual growth rate (CAGR) stands at +6.3%, showing solid earnings momentum. The company achieved its highest annual net income of $8.08B in fiscal 2021.
Regeneron Pharmaceuticals, Inc. maintains industry-leading profitability with a gross margin of 85.4%, operating margin of 24.9%, and net margin of 31.4%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including BIIB ($1.37B net income, 13.2% margin), VRTX ($4.34B net income, 32.7% margin), INCY ($1.43B net income, 25.0% margin), REGN has outperformed on profitability metrics. Compare REGN vs BIIB →
REGN Earnings vs Peers
Earnings metrics vs comparable public companies
REGN Historical Earnings Data (1991–2025)
35 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $4.50B | +2.1% | $3.58B | $41.48 | 31.4% | 24.9% |
| 2024 | $4.41B | +11.6% | $3.99B | $38.34 | 31.1% | 28.1% |
| 2023 | $3.95B | -8.9% | $4.35B | $34.77 | 30.1% | 33.2% |
| 2022 | $4.34B | -46.3% | $5.39B | $38.22 | 35.6% | 44.2% |
| 2021 | $8.08B | +129.9% | $8.95B | $71.97 | 50.2% | 55.7% |
| 2020 | $3.51B | +66.0% | $3.58B | $30.52 | 41.3% | 42.1% |
| 2019 | $2.12B | -13.4% | $2.21B | $18.46 | 32.3% | 33.7% |
| 2018 | $2.44B | +104.0% | $2.53B | $21.29 | 36.4% | 37.8% |
| 2017 | $1.20B | +33.8% | $2.08B | $10.34 | 20.4% | 35.4% |
| 2016 | $896M | +40.8% | $1.33B | $7.70 | 18.4% | 27.4% |
Full REGN Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See REGN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs REGN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare REGN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonREGN — Frequently Asked Questions
Quick answers to the most common questions about buying REGN stock.
Is REGN growing earnings?
REGN EPS stands at $41.07, with +8.2% growth matching the 5-year CAGR of +6.3%. TTM net income is $4.4B. Earnings trajectory remains consistent.
What are REGN's profit margins?
Regeneron Pharmaceuticals, Inc. net margin is +31.4%, with operating margin at +24.9%. Above-average margins indicate pricing power.
How consistent are REGN's earnings?
REGN earnings data spans 1991-2025. The current earnings trend is +8.2% YoY. Historical data enables comparison across business cycles.